Chiral hydroxymethyl-1 H ,3 H -pyrrolo[1,2- c ]thiazoles: the search for selective p53-activating agents for colorectal cancer therapy.
Mees M HendrikxAdelino M R PereiraAna B PereiraCarla S C CarvalhoJoão L P RibeiroMaria I L SoaresLucília SaraivaTeresa M V D Pinho E MeloPublished in: RSC medicinal chemistry (2024)
MANIO is an efficient p53-activating anticancer agent with remarkable selectivity to the p53 pathway and promising antitumor activity against colorectal cancer (CRC). Herein, a library of novel MANIO derivatives, including hydroxymethyl- and bis(hydroxymethyl)-1 H ,3 H -pyrrolo[1,2- c ]thiazoles, was synthesized by rational structural modulation. The antiproliferative activity of twenty derivatives was evaluated in a panel of human CRC cells with different p53 status. From this library, five compounds with R - and S -configuration and with aromatic or heteroaromatic groups at position 3, including the enantiomer of MANIO, were identified as selective towards p53-expressing cancer cells. On the other hand, two compounds with S -configuration, 6-hydroxymethyl- and 7-hydroxymethyl-5-methyl-3-phenyl-1 H ,3 H -pyrrolo[1,2- c ]thiazoles, showed high cytotoxicity against WTp53-expressing HCT116 colon cells but, unlike MANIO, exhibited p53-independent inhibitory activity in CRC. The results described provide relevant structural and pharmacophoric data for the design of new p53-activating agents for precision therapy of CRC or other p53-related cancers harboring both wild-type or mutated p53 forms.
Keyphrases
- wild type
- induced apoptosis
- cell cycle arrest
- signaling pathway
- cancer therapy
- endothelial cells
- cell death
- ionic liquid
- drug delivery
- endoplasmic reticulum stress
- big data
- oxidative stress
- young adults
- machine learning
- mass spectrometry
- mesenchymal stem cells
- bone marrow
- artificial intelligence
- deep learning
- cell therapy